Nektar Therapeutics
NKTR
197 hedge funds and large institutions have $2.96B invested in Nektar Therapeutics in 2017 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 99 increasing their positions, 50 reducing their positions, and 22 closing their positions.
199% more call options, than puts
Call options by funds: $31.7M | Put options by funds: $10.6M
98% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 50
0.15% more ownership
Funds ownership: 6.36% → 6.5% (+0.15%)
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
2% less funds holding
Funds holding: 201 → 197 (-4)
14% less capital invested
Capital invested by funds: $3.44B → $2.96B (-$477M)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$34.2M |
| 2 |
Primecap Management
Pasadena,
California
|
+$32.2M |
| 3 |
PC
PointState Capital
New York
|
+$24.6M |
| 4 |
O
OppenheimerFunds
New York
|
+$24M |
| 5 |
DFO
Duquesne Family Office
New York
|
+$9.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$28M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$15.7M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$12.5M |
| 4 |
JP Morgan Chase
New York
|
-$10.7M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$9.96M |
NKTR Hedge Fund Activity: Q2 2017 in Review
197 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2017, worth a combined $2.96B — down 14% from $3.44B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of NKTR and 20 opened new positions — a net loss of 2 holders — while 50 trimmed existing stakes and 99 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $34.2M. The largest seller was Fidelity Investments, cutting an estimated $28M.
- 197 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2017, down from 201 in Q1 2017.
- Funds reported $2.96B of Nektar Therapeutics stock for Q2 2017, down 14% quarter-over-quarter.
- 20 funds opened new Nektar Therapeutics positions in Q2 2017 and 22 closed out, a net change of -2 holders.
- The largest Nektar Therapeutics buyer in Q2 2017 was Janus Henderson Group, an estimated $34.2M added.
- The largest Nektar Therapeutics seller in Q2 2017 was Fidelity Investments, an estimated $28M sold.
Based on aggregated 13F filings for Q2 2017.